AbCellera Biologics Inc. (ABCL)
NASDAQ: ABCL · Real-Time Price · USD
4.160
0.00 (0.00%)
At close: Apr 28, 2026, 4:00 PM EDT
4.190
+0.030 (0.72%)
After-hours: Apr 28, 2026, 7:59 PM EDT
AbCellera Biologics Stock Forecast
Stock Price Forecast
The 5 analysts with 12-month price forecasts for AbCellera Biologics stock have an average target of 8.40, with a low estimate of 4.00 and a high estimate of 11. The average target predicts an increase of 101.92% from the current stock price of 4.16.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for AbCellera Biologics stock from 5 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Nov '25 | Dec '25 | Jan '26 | Feb '26 | Mar '26 | Apr '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 2 | 2 | 2 | 3 |
| Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Hold | 2 | 2 | 2 | 2 | 2 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 5 | 5 | 5 | 5 | 5 | 5 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Jones Trading | Jones Trading | Strong Buy Initiates $11 | Strong Buy | Initiates | $11 | +164.42% | Apr 10, 2026 |
| Leerink Partners | Leerink Partners | Buy → Hold Downgrades $4 | Buy → Hold | Downgrades | $4 | -3.85% | Nov 7, 2025 |
| Stifel | Stifel | Strong Buy Maintains $8 → $7 | Strong Buy | Maintains | $8 → $7 | +68.27% | Aug 8, 2025 |
| Keybanc | Keybanc | Buy Maintains $5 → $10 | Buy | Maintains | $5 → $10 | +140.38% | Jul 14, 2025 |
| Leerink Partners | Leerink Partners | Buy Initiates $5 | Buy | Initiates | $5 | +20.19% | Jul 7, 2025 |
Financial Forecast
Revenue This Year
31.15M
from 75.13M
Decreased by -58.53%
Revenue Next Year
37.96M
from 31.15M
Increased by 21.85%
EPS This Year
-0.77
from -0.49
EPS Next Year
-0.82
from -0.77
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 50.4M | 70.4M | ||||||
| Avg | 31.2M | 38.0M | ||||||
| Low | 19.5M | 25.0M |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | -32.9% | 125.8% | ||||||
| Avg | -58.5% | 21.9% | ||||||
| Low | -74.0% | -19.8% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | -0.63 | -0.63 | ||||||
| Avg | -0.77 | -0.82 | ||||||
| Low | -0.94 | -0.94 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | - | - | ||||||
| Avg | - | - | ||||||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.